Principal Investigator
Hadar Lev-Tov
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20250394
Clinical Trial Summary
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS2)
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other